Tumor Treating Fields (TTFields) are anti-mitotic treatments that inhibit tumor growth by disrupting cancer cell division and mitosis. TTFields use electric fields tuned to specific frequencies to disrupt cell division, thus slowing or stopping cancer progression. TTFields are delivered through transducer arrays placed on the skin of cancer patients which are connected to a portable medical device that generates the electric field. The use of TTFields has expanded and been approved for several advanced cancer indications such as glioblastoma, malignant pleural mesothelioma, and non-small cell lung cancer.
The global Tumor Treating Fields Market is estimated to be valued at US$ 333.8 Mn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends driving the growth of the tumor treating fields market is the increasing usage of TTFields therapy in combination with other cancer treatments such as chemotherapy. Studies have shown that combining TTFields therapy with chemotherapy enhances the efficacy of chemotherapy in cancer treatment and improves patient outcomes. For instance, in 2020, a study published in Lancet concluded that combining TTFields therapy with temozolomide chemotherapy improves progression-free and overall survival in patients with newly diagnosed glioblastoma. Such emerging evidence on the benefits of combining TTFields therapy with other cancer treatments is increasing its adoption rate and driving the market growth.
The global tumor treating fields market is segmented on the basis of equipment type, application, end user and region. By equipment type, the market is dominated by optune device segment as it provides non-invasive treatment through low intensity alternating electric fields to treat glioblastoma. It delivers electric fields at an intermediate frequency within the tumor that interferes with cell division, thereby inhibiting tumor growth.
The global tumor treating fields market is expected to witness high growth over the forecast period. The global Tumor Treating Fields Market is estimated to be valued at US$ 333.8 Mn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030.
Regional analysis: North America region currently dominates the global tumor treating fields market owing to increasing incidence of cancer and presence of advanced healthcare infrastructure in the region. The region is expected to continue its dominance over the forecast period.
Key players: Key players operating in the tumor treating fields market are Tier 1 Companie, Other Key Player 1 and Other Key Player 2. Tier 1 Companie currently dominates the global tumor treating fields market with its flagship Optune device approved for the treatment of glioblastoma. The company is further investing in research & development activities to expand the applications of tumor treating fields therapy to other difficult-to-treat cancers.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it